|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bergers G and Hanahan D: Modes of
resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clarke JM and Hurwitz HI: Understanding
and targeting resistance to anti-angiogenic therapies. J
Gastrointest Oncol. 4:253–263. 2013.PubMed/NCBI
|
|
5
|
Gacche RN and Meshram RJ: Angiogenic
factors as potential drug target: Efficacy and limitations of
anti-angiogenic therapy. Biochim Biophys Acta. 1846:161–179.
2014.PubMed/NCBI
|
|
6
|
Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason
GA, Christensen JG and Kerbel RS: Accelerated metastasis after
short-term treatment with a potent inhibitor of tumor angiogenesis.
Cancer Cell. 15:232–239. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Presta M, Dell'Era MP, Mitola S, Moroni E,
Ronca R and Rusnati M: Fibroblast growth factor/fibroblast growth
factor receptor system in angiogenesis. Cytokine Growth Factor Rev.
16:159–178. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kamba T and McDonald DM: Mechanisms of
adverse effects of anti-VEGF therapy for cancer. Br J Cancer.
96:1788–1795. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kubota Y: Tumor angiogenesis and
anti-angiogenic therapy. Keio J Med. 61:47–56. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Verheul HM and Pinedo HM: Possible
molecular mechanisms involved in the toxicity of angiogenesis
inhibition. Nat Rev Cancer. 7:475–485. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tartari RF, Ulbrich-Kulczynski JM and
Filho AF: Measurement of mid-arm muscle circumference and prognosis
in stage IV non-small cell lung cancer patients. Oncol Lett.
5:1063–1067. 2013.PubMed/NCBI
|
|
12
|
Shimizu T, Yokoi T, Tamaki T, Kibata K,
Inagaki N and Nomura S: Comparative analysis of carboplatin and
paclitaxel combination chemotherapy schedules in previously
untreated patients with advanced non-small cell lung cancer. Oncol
Lett. 5:761–767. 2013.PubMed/NCBI
|
|
13
|
Mutlu H, Buyukcelik A, Kaya E, Kibar M,
Seyrek E, Yavuz S and Calikuşu Z: Sunlight may increase the FDG
uptake value in primary tumors of patients with non-small cell lung
cancer. Oncol Lett. 5:773–776. 2013.PubMed/NCBI
|
|
14
|
Yan FC, Wang QQ, Ruan YH, Ma LJ, Jia JT
and Jin KW: Establishment and biological characteristics of lung
cancer cell line XWLC-05. Ai Zheng. 26:21–25. 2007.(In Chinese).
PubMed/NCBI
|
|
15
|
St Croix CM, Morgan BJ, Wetter TJ and
Dempsey JA: Fatiguing inspiratory muscle work causes reflex
sympathetic activation in humans. J Physiol. 529:493–504. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hotchkiss KA, Basile CM, Spring SC,
Bonuccelli G, Lisanti MP and Terman BI: TEM8 expression stimulates
endothelial cell adhesion and migration by regulating cell-matrix
interactions on collagen. Exp Cell Res. 305:133–144. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
She J, Yang P, Hong Q and Bai C: Lung
cancer in China: Challenges and interventions. Chest.
143:1117–1126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang L, Zhu LP and Wang X: Incidence and
mortality of lung cancer among residents covered by cancer registry
system in Jiangxi province, 2011–2013. Chin J Public Health.
32:654–657. 2016.
|
|
20
|
Reichardt P, Blay JY, Gelderblom H,
Schlemmer M, Demetri GD, Bui-Nguyen B, McArthur GA, Yazji S, Hsu Y,
Galetic I and Rutkowski P: Phase III study of nilotinib versus best
supportive care with or without a TKI in patients with
gastrointestinal stromal tumors resistant to or intolerant of
imatinib and sunitinib. Ann Oncol. 23:1680–1687. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee TT, García JR, Paez JI, Singh A,
Phelps EA, Weis S, Shafiq Z, Shekaran A, Del Campo A and García AJ:
Light-triggered in vivo activation of adhesive peptides regulates
cell adhesion, inflammation and vascularization of biomaterials.
Nat Mater. 14:352–360. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Möller B, Rasmussen C, Lindblom B and
Olovsson M: Expression of the angiogenic growth factors VEGF,
FGF-2, EGF and their receptors in normal human endometrium during
the menstrual cycle. Mol Hum Reprod. 7:65–72. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim DH, Sung B, Kang YJ, Hwang SY, Kim MJ,
Yoon JH, Im E and Kim ND: Sulforaphane inhibits hypoxia-induced
HIF-1α and VEGF expression and migration of human colon cancer
cells. Int J Oncol. 47:2226–2232. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang JC, Haworth L, Sherry RM, Hwu P,
Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX and
Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular
endothelial growth factor antibody, for metastatic renal cancer. N
Engl J Med. 349:427–434. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cainap C, Qin S, Huang WT, Chung IJ, Pan
H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, et al: Linifanib
versus Sorafenib in patients with advanced hepatocellular
carcinoma: Results of a randomized phase III trial. J Clin Oncol.
33:172–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tannir NM, Jonasch E, Albiges L,
Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Lim Dubauskas Z,
Tamboli P, et al: Everolimus versus sunitinib prospective
evaluation in metastatic non-clear cell renal cell carcinoma
(ESPN): A randomized multicenter phase 2 trial. Eur Urol.
69:866–874. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tang H, Ma H, Peng F, Bao Y, Hu X, Wang J,
Xu Y and Chen M: Prognostic performance of inflammation-based
prognostic indices in locally advanced non-small-lung cancer
treated with endostar and concurrent chemoradiotherapy. Mol Clin
Oncol. 4:801–806. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y,
Liu W, Tong J, Liu Y, Xu R, et al: Randomized, double-blind,
placebo-controlled phase iii trial of apatinib in patients with
chemotherapy-refractory advanced or metastatic adenocarcinoma of
the stomach or gastroesophageal junction. J Clin Oncol.
34:1448–1454. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Whittaker CA and Hynes RO: Distribution
and evolution of von Willebrand/integrin A domains: Widely
dispersed domains with roles in cell adhesion and elsewhere. Mol
Biol Cell. 13:3369–3387. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hood JD and Cheresh DA: Role of integrins
in cell invasion and migration. Nat Rev Cancer. 2:91–100. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rmali KA, Puntis MC and Jiang WG:
Prognostic values of tumor endothelial markers in patients with
colorectal cancer. World J Gastroenterol. 11:1283–1286. 2005.
View Article : Google Scholar : PubMed/NCBI
|
